| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
25,710,000 |
| Market
Cap: |
7.93(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,248,166 |
| 52
Week Range: |
$202.48 - $355.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
424,685 |
| Total Buy Value |
$0 |
$0 |
$0 |
$77,751,391 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
10 |
| Total Shares Sold |
0 |
60,368 |
84,419 |
381,986 |
| Total Sell Value |
$0 |
$20,754,419 |
$28,104,803 |
$100,453,455 |
| Total People Sold |
0 |
8 |
10 |
12 |
| Total Sell Transactions |
0 |
15 |
21 |
46 |
| End Date |
2025-04-10 |
2025-01-07 |
2024-07-09 |
2023-07-10 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bate Kenneth |
Director |
– • – |
2025-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
715 |
2,627 |
|
- |
|
| Daly James M |
Director |
– • – |
2025-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
715 |
2,627 |
|
- |
|
| Baker Julian |
|
– • – |
2025-06-20 |
4 |
A |
$0.00 |
$0 |
I/I |
2,860 |
1,796,261 |
|
- |
|
| Fouse Jacqualyn A |
Director |
– • – |
2025-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
203 |
1,097 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2025-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
715 |
187,164 |
|
- |
|
| Levy Richard S |
Director |
– • – |
2025-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
715 |
21,197 |
|
- |
|
| Soergel David |
Chief Medical Officer |
• – – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,545 |
7,545 |
|
- |
|
| Levy Richard S |
Director |
– • – |
2025-04-10 |
4 |
OE |
$65.06 |
$616,118 |
D/D |
9,470 |
20,482 |
|
- |
|
| Dier Mardi |
SVP and CFO |
• – – |
2025-03-10 |
4 |
AS |
$323.04 |
$83,344 |
D/D |
(258) |
10,440 |
|
-9% |
|
| Fouse Jacqualyn A |
Director |
– • – |
2025-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
894 |
894 |
|
- |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2025-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,382 |
461,044 |
|
- |
|
| Sibold William John |
President and CEO |
• • – |
2025-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
13,066 |
117,369 |
|
- |
|
| Dier Mardi |
SVP and CFO |
• – – |
2025-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,784 |
10,698 |
|
- |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2025-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,061 |
5,789 |
|
- |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2025-03-05 |
4 |
S |
$335.15 |
$4,817,104 |
D/D |
(14,113) |
3,728 |
|
11% |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2025-03-05 |
4 |
OE |
$87.09 |
$1,234,766 |
D/D |
14,113 |
17,841 |
|
- |
|
| Kelley Shannon T |
General Counsel |
• – – |
2025-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,187 |
10,477 |
|
- |
|
| Huntsman Carole |
Chief Commercial Officer |
• – – |
2025-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,386 |
11,990 |
|
- |
|
| Huntsman Carole |
Chief Commercial Officer |
• – – |
2025-03-03 |
4 |
AS |
$313.08 |
$597,840 |
D/D |
(1,834) |
8,604 |
|
-5% |
|
| Dier Mardi |
SVP and CFO |
• – – |
2025-03-03 |
4 |
AS |
$323.54 |
$637,248 |
D/D |
(1,961) |
6,914 |
|
-5% |
|
| Kelley Shannon T |
General Counsel |
• – – |
2025-03-03 |
4 |
AS |
$335.00 |
$139,025 |
D/D |
(415) |
7,290 |
|
-5% |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2025-02-28 |
4 |
S |
$340.99 |
$418,488 |
D/D |
(1,227) |
3,728 |
|
10% |
|
| Daly James M |
Director |
– • – |
2025-02-27 |
4 |
S |
$346.90 |
$5,375,126 |
D/D |
(15,470) |
1,912 |
|
8% |
|
| Daly James M |
Director |
– • – |
2025-02-27 |
4 |
OE |
$65.06 |
$1,282,478 |
D/D |
15,470 |
17,382 |
|
- |
|
| Sibold William John |
President and CEO |
• • – |
2025-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
104,303 |
|
- |
|
228 Records found
|
|
Page 1 of 10 |
|
|
21.07 (7.33%) 
